Skip to main content

Table 2 Summary of the multivariable analyses of prognostic factors

From: Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Variable

OS

DSS

DMFS

LRFS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

IC regimen (PF vs. TPF)

0.660 (0.442–0.986)

0.042

0.624 (0.411–0.947)

0.027

0.589 (0.406–0.855)

0.005

1.213 (0.719–2.047)

0.469

Gender (male vs. female)

0.812 (0.581–1.135)

0.223

0.727 (0.510–1.037)

0.079

0.918 (0.640–1.317)

0.643

0.649 (0.381–1.106)

0.112

Age

1.027 (1.016–1.039)

0.001

1.024 (1.012–1.036)

0.001

1.013 (1.000–1.025)

0.044

1.020 (1.003–1.037)

0.023

Smoking (yes vs. no)

1.041 (0.796–1.363)

0.768

1.003 (0.760–1.323)

0.985

0.944 (0.694–1.285)

0.715

0.976 (0.648–1.472)

0.909

T stage (T1–2 vs. T3–4)

1.393 (1.178–1.648)

0.001

1.231 (0.979–1.549)

0.075

1.306 (1.086–1.570)

0.005

1.420 (1.094–1.842)

0.008

N stage (N0–1 vs. N2–3)

1.308 (1.135–1.509)

0.001

1.177 (1.028–1.349)

0.018

1.547 (1.312–1.824)

0.001

1.146 (0.902–1.456)

0.266

Clinical stage (III vs. IV)

1.185 (0.855–1.642)

0.309

1.630 (1.268–2.097)

0.027

1.012 (0.701–1.460)

0.951

0.909 (0.526–1.572)

0.734

CDDP dose (< 200 mg/m2 vs. ≥ 200 mg/m2)

0.884 (0.695–1.125)

0.316

0.869 (0.676–1.118)

0.276

1.012 (0.772–1.327)

0.930

1.054 (0.728–1.526)

0.782

Number of IC cycles (< 2 cycles vs. ≥ 2 cycles)

1.089 (0.782–1.518)

0.613

1.121 (0.788–1.593)

0.526

1.217 (0.809–1.829)

0.346

0.899 (0.551–1.467)

0.670

Time to RT (< 60 days vs. ≥ 60 days)

0.874 (0.650–1.173)

0.369

0.840 (0.618–1.142)

0.265

1.102 (0.807–1.506)

0.541

0.857 (0.548–1.339)

0.498

Radiation technique (IMRT vs. 2D-CRT)

1.540 (1.134–2.091)

0.006

1.442 (1.053–1.975)

0.022

1.273 (0.914–1.775)

0.153

1.015 (0.654–1.574)

0.948

  1. IC induction chemotherapy, TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, CDDP dose the cisplatin dose of concurrent chemotherapy, RT radiotherapy, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy, HR hazard ratio